166 related articles for article (PubMed ID: 10773878)
1. Analysis of p73 in human borderline and invasive ovarian tumor.
Ng SW; Yiu GK; Liu Y; Huang LW; Palnati M; Jun SH; Berkowitz RS; Mok SC
Oncogene; 2000 Apr; 19(15):1885-90. PubMed ID: 10773878
[TBL] [Abstract][Full Text] [Related]
2. P73 gene expression in ovarian cancer tissues and cell lines.
Chen CL; Ip SM; Cheng D; Wong LC; Ngan HY
Clin Cancer Res; 2000 Oct; 6(10):3910-5. PubMed ID: 11051237
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines.
Zaika AI; Kovalev S; Marchenko ND; Moll UM
Cancer Res; 1999 Jul; 59(13):3257-63. PubMed ID: 10397274
[TBL] [Abstract][Full Text] [Related]
4. Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target.
Imyanitov EN; Birrell GW; Filippovich I; Sorokina N; Arnold J; Mould MA; Wright K; Walsh M; Mok SC; Lavin MF; Chenevix-Trench G; Khanna KK
Oncogene; 1999 Aug; 18(32):4640-2. PubMed ID: 10467409
[TBL] [Abstract][Full Text] [Related]
5. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line.
Vikhanskaya F; D'Incalci M; Broggini M
Nucleic Acids Res; 2000 Jan; 28(2):513-9. PubMed ID: 10606650
[TBL] [Abstract][Full Text] [Related]
6. Allelic expression of the putative tumor suppressor gene p73 in human fetal tissues and tumor specimens.
Hu JF; Ulaner GA; Oruganti H; Ivaturi RD; Balagura KA; Pham J; Vu TH; Hoffman AR
Biochim Biophys Acta; 2000 Apr; 1491(1-3):49-56. PubMed ID: 10760569
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
8. p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo.
Perez-Losada J; Wu D; DelRosario R; Balmain A; Mao JH
Oncogene; 2005 Aug; 24(35):5521-4. PubMed ID: 16007185
[TBL] [Abstract][Full Text] [Related]
9. Expression profiles of p53, p63, and p73 in benign salivary gland tumors.
Weber A; Langhanki L; Schütz A; Gerstner A; Bootz F; Wittekind C; Tannapfel A
Virchows Arch; 2002 Nov; 441(5):428-36. PubMed ID: 12447671
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of p73 and p53 in human cancer cell lines.
Yoshikawa H; Nagashima M; Khan MA; McMenamin MG; Hagiwara K; Harris CC
Oncogene; 1999 Jun; 18(22):3415-21. PubMed ID: 10362363
[TBL] [Abstract][Full Text] [Related]
11. Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma.
Nicholson SA; Okby NT; Khan MA; Welsh JA; McMenamin MG; Travis WD; Jett JR; Tazelaar HD; Trastek V; Pairolero PC; Corn PG; Herman JG; Liotta LA; Caporaso NE; Harris CC
Cancer Res; 2001 Jul; 61(14):5636-43. PubMed ID: 11454718
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of p73 splice variants and protein in benign and malignant ovarian tumours.
Zwahlen D; Tschan MP; Grob TJ; Peters UR; Fink D; Haenggi W; Altermatt HJ; Cajot JF; Tobler A; Fey MF; Aebi S
Int J Cancer; 2000 Oct; 88(1):66-70. PubMed ID: 10962441
[TBL] [Abstract][Full Text] [Related]
13. Quantitative TP73 transcript analysis in hepatocellular carcinomas.
Stiewe T; Tuve S; Peter M; Tannapfel A; Elmaagacli AH; Pützer BM
Clin Cancer Res; 2004 Jan; 10(2):626-33. PubMed ID: 14760085
[TBL] [Abstract][Full Text] [Related]
14. Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells.
Sayan AE; Sayan BS; Findikli N; Ozturk M
Oncogene; 2001 Aug; 20(37):5111-7. PubMed ID: 11526499
[TBL] [Abstract][Full Text] [Related]
15. Expression of homologues for p53 and p73 in the softshell clam (Mya arenaria), a naturally-occurring model for human cancer.
Kelley ML; Winge P; Heaney JD; Stephens RE; Farell JH; Van Beneden RJ; Reinisch CL; Lesser MP; Walker CW
Oncogene; 2001 Feb; 20(6):748-58. PubMed ID: 11314008
[TBL] [Abstract][Full Text] [Related]
16. A naturally occurring p73 mutation in a p73-p53 double-mutant lung cancer cell line encodes p73 alpha protein with a dominant-negative function.
Huqun ; Endo Y; Xin H; Takahashi M; Nukiwa T; Hagiwara K
Cancer Sci; 2003 Aug; 94(8):718-24. PubMed ID: 12901798
[TBL] [Abstract][Full Text] [Related]
17. Frequent allelic losses on the short arm of chromosome 1 and decreased expression of the p73 gene at 1p36.3 in squamous cell carcinoma of the oral cavity.
Araki D; Uzawa K; Watanabe T; Shiiba M; Miyakawa A; Yokoe H; Tanzawa H
Int J Oncol; 2002 Feb; 20(2):355-60. PubMed ID: 11788901
[TBL] [Abstract][Full Text] [Related]
18. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors].
Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848
[TBL] [Abstract][Full Text] [Related]
19. Two new p73 splice variants, gamma and delta, with different transcriptional activity.
De Laurenzi V; Costanzo A; Barcaroli D; Terrinoni A; Falco M; Annicchiarico-Petruzzelli M; Levrero M; Melino G
J Exp Med; 1998 Nov; 188(9):1763-8. PubMed ID: 9802988
[TBL] [Abstract][Full Text] [Related]
20. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
